Personalized cancer vaccines: A new frontier in lung cancer treatment and prevention
“Despite declining tobacco use, lung cancer remains the leading cause of cancer-related death worldwide. As oncologists seek more-effective and individualized therapies, Mayo Clinic researchers are advancing a promising frontier: cancer vaccines. These immunotherapies are designed not only to treat existing disease but also to prevent recurrence and, potentially, primary onset in high-risk populations.”
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
“BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after approximately four years. Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population.”
Addressing Drug Resistance in Lung Cancer
“Key Takeaways: Drug resistance in lung cancer arises from pre-existing resistant clones and drug-tolerant states, complicating treatment strategies. Combination therapies and advanced inhibitors can preemptively address resistance pathways, improving response rates in targeted therapies.”
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
“Treatment with tarlatamab-dlle (Imdelltra) improved overall survival (OS) vs chemotherapy among patients with small cell lung cancer (SCLC) regardless of chemotherapy-free intervals (CFIs) or prior receipt of anti–PD-(L)1 therapy, according to data from the phase 3 DeLLphi-304 trial (NCT05740566) presented at the European Society for Medical Oncology (ESMO) Congress 2025.”
Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer
“Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.”
New Exosomal Proteins Uncovered as Lung Cancer Biomarkers
“In a groundbreaking study that promises to revolutionize the early detection of lung cancer, Feng et al. have unveiled a set of novel exosomal protein biomarkers. These biomarkers emerged from an extensive proteomic profiling approach, specifically devised to enhance diagnostic capabilities.”
First-Line Alectinib Yields Clinically Meaningful OS Benefit in Advanced ALK+ NSCLC
“Key Takeaways: Alectinib improved overall survival in advanced ALK-positive NSCLC compared to crizotinib, though results were not statistically significant. Patients with CNS metastases who received radiation showed the most benefit from alectinib.”
ESMO 2025: Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer
“Lung cancer is the leading cause of cancer-related death worldwide, with up to 4% of non-small cell lung cancer cases having a HER2 gene mutation. Sevabertinib is an oral drug targeting HER2 mutations that shrinks tumors in advanced lung cancer patients, with minimal side effects. FDA granted priority review for sevabertinib, and results of this study will help inform the decision.”
New drug shows dramatic effect in shrinking lung cancer tumours
“A trial testing the drug zongertinib as a first treatment for people with advanced lung cancer who have a HER2 genetic mutation shows it can eradicate tumours in some patients while reducing their size in others.”
Most lung cancer is diagnosed at Stage 4: How Md. health system catches 40% at Stage 1
“Frederick Health Medical Group, in Frederick, Maryland, identifies lung cancer early by investigating tiny clues, which enables patients to get to cancer specialists earlier in the process, according to a doctor with the group.”
New Mobile Lung Cancer Screening Unit Launches to Improve Access to Care for New Yorkers
“A state-of-the-art health screening van launched this month is bringing advanced imaging technology and health education directly to New Yorkers who are at the greatest risk of developing lung cancer. The initiative — a collaboration between Weill Cornell Imaging at NewYork-Presbyterian, the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center, and the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine — is designed to make early lung cancer detection more accessible and equitable.”
